In short
A new clinical trial is underway to evaluate the potential of mRNA-1010, a candidate seasonal influenza vaccine. This study aims to compare the safety, effectiveness, and immune response of mRNA-1010 to a licensed inactivated seasonal influenza vaccine in adults aged 50 and older. The trial will assess various aspects of the vaccine's performance, including its ability to prevent influenza-like illness and generate protective antibodies.
At a glance
- Study Type
- Phase 3, Randomized, Observer-blind, Active-controlled
- Participant Age
- 50 years and older
- Main Objective
- Evaluate safety, efficacy, and immunogenicity of mRNA-1010
- Comparison
- mRNA-1010 vs. licensed inactivated seasonal influenza vaccine
- Primary Endpoints
- Adverse reactions, influenza-like illness occurrence
- Secondary Endpoints
- Antibody levels, seroconversion rates
- Study Duration
- Approximately 181 days
- Key Exclusions
- Recent illness, certain vaccinations, severe allergies to vaccines
What is CX-037231?
CX-037231 is an active substance that is part of a new influenza vaccine called mRNA-1010. This vaccine is currently being studied to see how well it works and how safe it is for adults who are 50 years old or older. The vaccine is given as an injection into the muscle (intramuscular injection).
How does CX-037231 work?
CX-037231 is part of an mRNA vaccine. mRNA stands for messenger ribonucleic acid, which is a type of genetic material. This vaccine uses mRNA technology to teach your body how to fight against the flu virus. It's different from traditional flu vaccines because it doesn't contain the actual virus. Instead, it gives your cells instructions to make a harmless piece of the virus. This helps your immune system recognize and fight the real virus if you're exposed to it later.
What conditions does CX-037231 treat?
CX-037231, as part of the mRNA-1010 vaccine, is designed to prevent influenza (commonly known as the flu) in adults aged 50 and older. Influenza is a viral infection that can cause symptoms like fever, cough, body aches, and fatigue. It can be especially serious for older adults, which is why this vaccine is being studied in this age group.
Ongoing Clinical Trial
A large clinical trial (known as a Phase 3 trial) is currently underway to study mRNA-1010, which contains CX-037231. This trial aims to:
- Compare the safety and effectiveness of mRNA-1010 to an already approved flu vaccine
- See how well mRNA-1010 protects against flu-like illness caused by any type of influenza A or B virus
- Measure the immune response produced by mRNA-1010
Eligibility Criteria
To participate in this study, individuals must meet certain criteria. Some key points include:
- Be 50 years of age or older
- Be capable of giving informed consent
- Not have received a flu vaccine in the past 180 days
- Not have had a flu infection in the past 180 days
- Not have certain medical conditions that might affect the study results
There are also specific requirements for women who can become pregnant, including using acceptable contraception methods.
Safety and Effectiveness Measures
The study will closely monitor participants for any side effects and measure how well the vaccine works. Some key things they'll be looking at include:
- Local reactions at the injection site (like pain or swelling) and systemic reactions (like fever or fatigue) in the week after vaccination
- Any unexpected side effects in the month after vaccination
- Serious side effects or medically important events for about 6 months after vaccination
- How well the vaccine prevents flu-like illness
- The body's immune response to the vaccine, measured by blood tests
This thorough evaluation will help determine if mRNA-1010, containing CX-037231, is safe and effective for preventing flu in older adults.